{"id":10619,"date":"2011-08-04T14:35:04","date_gmt":"2011-08-04T18:35:04","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=10619"},"modified":"2011-08-04T14:35:04","modified_gmt":"2011-08-04T18:35:04","slug":"easy-come-easy-go-esc-to-review-dronedarones-role-in-af-guidelines","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/08\/04\/easy-come-easy-go-esc-to-review-dronedarones-role-in-af-guidelines\/","title":{"rendered":"Easy Come, Easy Go? ESC to Review Dronedarone&#8217;s Role in AF Guidelines"},"content":{"rendered":"<p>Less than a year after\u00a0<a href=\"http:\/\/cardiobrief.org\/2010\/08\/30\/dronedarone-and-ticagrelor-speed-into-esc-guidelines\/\">speeding into the European Society of Cardiology&#8217;s atrial fibrillation guidelines<\/a> with a class 1 recommendation, the role of dronedarone (Multaq, Sanofi) in the treatment of AF will be reconsidered.<\/p>\n<p>&#8220;The ESC will produce a focused update of the AF Guidelines when the full results of PALLAS have been published and regulatory authorities have revised the labelling for dronedarone,&#8221; <a href=\"http:\/\/www.escardio.org\/about\/press\/press-releases\/pr-11\/Pages\/ESC-updates-atrial-fibrillation-guidelines.aspx\">the ESC announced today<\/a>.<\/p>\n<p>Since the publication of the ESC guidelines last September, dronedarone has sparked concerns related to\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/fda-warns-about-severe-liver-injury-associated-with-multaq-dronedarone\/\">several cases of severe liver injury<\/a>.\u00a0Then <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/dronedarone-multaq-study-for-permanent-af-stopped-early\/\">the PALLAS trial was terminated early<\/a>\u00a0due to an increase in cardiovascular events in patients with permanent AF treated with dronedarone.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Less than a year after\u00a0speeding into the European Society of Cardiology&#8217;s atrial fibrillation guidelines with a class 1 recommendation, the role of dronedarone (Multaq, Sanofi) in the treatment of AF will be reconsidered. &#8220;The ESC will produce a focused update of the AF Guidelines when the full results of PALLAS have been published and regulatory [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[410,326,595,409,917],"class_list":["post-10619","post","type-post","status-publish","format-standard","hentry","category-electrophysiology","tag-dronedarone","tag-esc","tag-guidelines","tag-multaq","tag-pallas"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/10619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=10619"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/10619\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=10619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=10619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=10619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}